| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $557,064 | 10 | 100 |
| Winter Charles M. | Chief Technical Officer | 0 | $0 | 1 | $32,966 | $-32,966 |
| DiRaimondo Thomas | Chief Scientific Officer | 0 | $0 | 1 | $34,394 | $-34,394 |
| McIver Zachariah | Chief Medical Officer | 0 | $0 | 1 | $37,263 | $-37,263 |
| Dobek Maria | Vice President, Accounting | 0 | $0 | 2 | $48,952 | $-48,952 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | 0 | $0 | 1 | $56,944 | $-56,944 |
| Campbell David Alan | President and CEO | 0 | $0 | 1 | $110,829 | $-110,829 |
| Meyer Andrew Hollman | Chief Business Officer | 0 | $0 | 3 | $235,718 | $-235,718 |
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface …
Over the last 12 months, insiders at Janux Therapeutics, Inc. have bought $0 and sold $557,064 worth of Janux Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Janux Therapeutics, Inc. have bought $33.39M and sold $91.32M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 110,206 shares for transaction amount of $3.42M was made by RA CAPITAL MANAGEMENT, L.P. () on 2025‑03‑07.
| 2026-06-02 | Sale | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | 4,059 0.0068% | $14.03 | $56,944 | +19.88% | |
| 2026-05-11 | Sale | Dobek Maria | Vice President, Accounting | 2,038 0.0033% | $14.17 | $28,878 | +14.27% | |
| 2026-01-02 | Sale | Campbell David Alan | President and CEO | 8,072 0.0134% | $13.73 | $110,829 | +9.19% | |
| 2026-01-02 | Sale | DiRaimondo Thomas | Chief Scientific Officer | 2,505 0.0041% | $13.73 | $34,394 | +9.19% | |
| 2026-01-02 | Sale | Meyer Andrew Hollman | Chief Business Officer | 1,879 0.0031% | $13.73 | $25,799 | +9.19% | |
| 2026-01-02 | Sale | Winter Charles M. | Chief Technical Officer | 2,401 0.004% | $13.73 | $32,966 | +9.19% | |
| 2026-01-02 | Sale | McIver Zachariah | Chief Medical Officer | 2,714 0.0045% | $13.73 | $37,263 | +9.19% | |
| 2026-01-02 | Sale | Dobek Maria | Vice President, Accounting | 1,462 0.0024% | $13.73 | $20,073 | +9.19% | |
| 2025-12-01 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,333 0.0054% | $32.98 | $109,929 | -56.25% | |
| 2025-11-14 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,333 0.0061% | $30.00 | $99,990 | -48.98% | |
| 2025-10-28 | Sale | Meyer Andrew Hollman | Chief Business Officer | 16,665 0.0341% | $30.06 | $500,987 | -49.46% | |
| 2025-05-01 | Sale | Meyer Andrew Hollman | Chief Business Officer | 2,933 0.0049% | $31.95 | $93,703 | -27.49% | |
| 2025-05-01 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,333 0.0056% | $32.03 | $106,745 | -27.49% | |
| 2025-04-21 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0069% | $30.00 | $100,020 | -19.76% | |
| 2025-03-07 | RA CAPITAL MANAGEMENT, L.P. | 110,206 0.187% | $31.02 | $3.42M | -20.72% | |||
| 2025-03-06 | RA CAPITAL MANAGEMENT, L.P. | 372,093 0.6366% | $30.78 | $11.45M | -20.98% | |||
| 2025-03-05 | RA CAPITAL MANAGEMENT, L.P. | 341,742 0.5742% | $30.64 | $10.47M | -22.83% | |||
| 2025-03-03 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0059% | $32.15 | $107,174 | -23.34% | |
| 2025-02-03 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0056% | $42.29 | $140,999 | -40.08% | |
| 2025-01-07 | Sale | Campbell David Alan | President and CEO | 5,000 0.009% | $60.00 | $300,004 | -55.35% |
| RA CAPITAL MANAGEMENT, L.P. | 10141287 16.5879% | $180.72M | 6 | 0 | <0.0001% | |
| Bregua Corp | 10 percent owner | 3749250 6.1326% | $66.81M | 1 | 0 | +1.61% |
| Reardon Tighe | Acting Chief Financial Officer | 633673 1.0365% | $11.29M | 2 | 1 | +1.61% |
| Avalon Ventures XI, L.P. | 10 percent owner | 401321 0.6564% | $7.15M | 2 | 11 | +1.61% |
| ORBIMED ADVISORS LLC | director | 231098 0.378% | $4.12M | 1 | 3 | +1.61% |
| Thompson Peter A. | director | 231098 0.378% | $4.12M | 1 | 3 | +1.61% |
| Lichter Jay | 10 percent owner | 7000 0.0114% | $124,740.00 | 2 | 2 | +1.61% |
$831,902,292 | 108 | 9.34% | $1.2B | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$11,663,618 | 57 | 32.20% | $934.29M | |
$135,656,796 | 20 | 30.67% | $1.43B | |
$24,007,605 | 16 | -20.65% | $1.33B |
| Increased Positions | 118 | +63.44% | 16M | +24.67% |
| Decreased Positions | 82 | -44.09% | 19M | -28.76% |
| New Positions | 44 | New | 4M | New |
| Sold Out Positions | 41 | Sold Out | 7M | Sold Out |
| Total Postitions | 222 | +19.35% | 63M | -4.09% |
| Ra Capital Management, L.P. | $152,739.00 | 18.65% | 11.19M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $123,615.00 | 15.09% | 9.06M | +167,320 | +1.88% | 2025-09-30 |
| Janus Henderson Group Plc | $64,170.00 | 7.84% | 4.7M | +240,780 | +5.4% | 2025-09-30 |
| Blackrock, Inc. | $50,928.00 | 6.22% | 3.73M | +328,147 | +9.64% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $39,862.00 | 4.87% | 2.92M | 0 | 0% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $37,879.00 | 4.63% | 2.77M | +250,000 | +9.9% | 2025-09-30 |
| Vanguard Group Inc | $32,993.00 | 4.03% | 2.42M | +227,676 | +10.4% | 2025-09-30 |
| State Street Corp | $25,818.00 | 3.15% | 1.89M | +503,357 | +36.26% | 2025-09-30 |
| Orbimed Advisors Llc | $24,107.00 | 2.94% | 1.77M | +555,800 | +45.92% | 2025-09-30 |
| Point72 Asset Management, L.P. | $23,344.00 | 2.85% | 1.71M | -433,700 | -20.23% | 2025-09-30 |